Epigenetic therapy in non-small-cell lung cancer: Targeting DNA methyltransferases and histone deacetylases

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1273-1285

  Vendetti, Frank P ^a   Rudin, Charles M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Azacitidine; Entinostat; Epigenetics; Histones; Lung cancer; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CARBOPLATIN; DNA METHYLTRANSFERASE; ENTINOSTAT; EPIRUBICIN; ERLOTINIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HYDRALAZINE; HYDROLASE; PACLITAXEL; ROMIDEPSIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ARTICLE; CANCER GROWTH; DNA METHYLATION; DRUG TOLERABILITY; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NONHUMAN; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84881513270     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.819337     Document Type: Article

References (122)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. Cancer J Clin 2011; 61: 69-90
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin 2013; 63: 11-30
3. Pao W, Miller V, Zakowski M, et al. Egf Receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11 (Pubitemid 39209661)
4. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic Egfr mutations. J Clin Oncol 2008; 26: 2442-9
5. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with Alk-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-19
6. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of Egfr/Kras and presence of Pik3ca/ Akt1 mutations. Clin Cancer Res 2012; 18: 1167-76
7. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-9
8. Choi YL, Soda M, Yamashita Y, et al. Eml4-Alk mutations in lung cancer that confer resistance to Alk inhibitors. N Engl J Med 2010; 363: 1734-9
9. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in Alk-rearranged lung cancers. Scil Med 2012; 4: 120ra17
10. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28 (Pubitemid 34587077)
11. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98 (Pubitemid 46439286)
12. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92 (Pubitemid 46273572)
13. Daskalos A, Nikolaidis G, Xinarianos G, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009; 124: 81-7
14. Ehrlich M. DNA Hypomethylation in cancer cells. Epigenomics 2009; 1: 239-59
15. Wolff EM, Byun HM, Han HF, et al. Hypomethylation of a line-1 promoter activates an alternate transcript of the met oncogene in bladders with cancer. PLoS Genet 2010; 6: e1000917
16. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400
17. Wen B, Wu H, Shinkai Y, et al. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet 2009; 41: 246-50
18. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific Cpg Island shores. Nat Genet 2009; 41: 178-86
19. Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768-75
20. Keshet I, Schlesinger Y, Farkash S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet 2006; 38: 149-53 (Pubitemid 43177227)
21. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007; 39: 237-42 (Pubitemid 46184356)
22. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39: 157-8 (Pubitemid 46184343)
23. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-Mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232-6 (Pubitemid 46184355)
24. Gal-Yam EN, Egger G, Iniguez L, et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the pc3 prostate cancer cell line. Proc Natl Acad Sci USA 2008; 105: 12979-84
25. Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012; 22: 837-49
26. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11: 726-34
27. Bachman KE, Park BH, Rhee I, et al. Histone Modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3: 89-95 (Pubitemid 37443893)
28. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004; 23: 138-49 (Pubitemid 38165754)
29. Strunnikova M, Schagdarsurengin U, Kehlen A, et al. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the rassf1a promoter. Mol Cell Biol 2005; 25: 3923-33 (Pubitemid 40617644)
30. Coolen MW, Stirzaker C, Song JZ, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (Lres) reduces transcriptional plasticity. Nat Cell Biol 2010; 12: 235-46
31. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9 (Pubitemid 32695003)
32. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-55 (Pubitemid 32095725)
33. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-17 (Pubitemid 39215069)
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74
35. Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 1999; 96: 12754-9 (Pubitemid 29513575)
36. Licchesi JD, Westra WH, Hooker CM, et al. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008; 14: 2570-8
37. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008; 29: 895-904 (Pubitemid 351982232)
38. Sterlacci W, Tzankov A, Veits L, et al. A comprehensive analysis of P16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thor Oncol 2011; 6: 1649-57
39. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-28 (Pubitemid 351398486)
40. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nate Rev Cancer 2006; 6: 107-16 (Pubitemid 43361543)
41. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with Mrna expression. Genome Res 2012; 22: 1197-211
42. Shinjo K, Okamoto Y, An B, et al. Integrated analysis of genetic and epigenetic alterations reveals Cpg Island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. Carcinogenesis 2012; 33: 1277-85
43. Toyota M, Ahuja N, Ohe-Toyota M, et al. Cpg Island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96: 8681-6 (Pubitemid 29354851)
44. Lockwood WW, Wilson IM, Coe BP, et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PloS One 2012; 7: e37775
45. Jeong S, Liang G, Sharma S, et al. Selective anchoring of DNA methyltransferases 3a and 3b to nucleosomes containing methylated DNA. Mol Cell Biol 2009; 29: 5366-76
46. Jones PA, Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10: 805-11
47. Rhee I, Jair KW, Yen RW, et al. Cpg methylation is maintained in human cancer cells lacking Dnmt1. Nature 2000; 404: 1003-7 (Pubitemid 30243595)
48. Rhee I, Bachman KE, Park BH, et al. Dnmt1 and Dnmt3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-6 (Pubitemid 34288859)
49. Jair KW, Bachman KE, Suzuki H, et al. De Novo Cpg Island methylation in human cancer cells. Cancer Res 2006; 66: 682-92 (Pubitemid 43165930)
50. Kim H, Kwon YM, Kim JS, et al. Elevated Mrna levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006; 107: 1042-9 (Pubitemid 44291153)
51. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5'cpg methylation and poor prognosis in lung cancer. Lung Cancer 2007; 55: 205-13
52. Lin RK, Wu CY, Chang JW, et al. Dysregulation of P53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 70: 5807-17
53. Tang YA, Lin RK, Tsai YT, et al. Mdm2 Overexpression deregulates the transcriptional control of Rb/E2f leading to DNA methyltransferase 3a overexpression in lung cancer. Clin Cancer Res 2012; 18: 4325-33
54. Iorio MV, Piovan C, Croce CM. Interplay between micrornas and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010; 1799: 694-701
55. Fabbri M, Garzon R, Cimmino A, et al. Microrna-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proc Natl Acad Sci USA 2007; 104: 15805-10 (Pubitemid 350035380)
56. Garzon R, Liu S, Fabbri M, et al. Microrna-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly Dnmt3a and 3b and indirectly Dnmt1. Blood 2009; 113: 6411-18
57. Agoston AT, Argani P, Yegnasubramanian S, et al. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 2005; 280: 18302-10 (Pubitemid 41389076)
58. Zhou Q, Agoston AT, Atadja P, et al. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast Cancer cells. Mol Cancer Res 2008; 6: 873-83
59. Wang J, Hevi S, Kurash JK, et al. The lysine demethylase Lsd1 (Kdm1) is required for maintenance of global DNA methylation. Nat Genet 2009; 41: 125-9
60. Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 Mrna expression in lung cancer. Lung Cancer 2004; 46: 171-8 (Pubitemid 39330411)
61. Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011; 74: 300-4
62. Lv T, Yuan D, Miao X, et al. Over-expression of Lsd1 promotes proliferation, migration and invasion in non-small cell lung cancer. PloS One 2012; 7: e35065
63. Wang L, Wang J, Sun S, et al. A novel Dnmt3b subfamily, delta Dnmt3b, is the predominant form of Dnmt3b in non-small cell lung cancer. Int J Oncol 2006; 29: 201-7
64. Wang J, Walsh G, Liu DD, et al. Expression of delta Dnmt3b variants and its association with promoter methylation of p16 and rassf1a in primary non-small cell lung cancer. Cancer Res 2006; 66: 8361-6 (Pubitemid 44449145)
65. Kim MS, Kim YR, Yoo NJ, et al. Mutational analysis of dnmt3a gene in acute leukemias and common solid cancers. APMIS 2013; 121: 85-94
66. Gao Q, Steine EJ, Barrasa MI, et al. Deletion of the De Novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci USA 2011; 108: 18061-6
67. Wu H, Coskun V, Tao J, et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010; 329: 444-8
68. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44: 23-31
69. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-22
70. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010; 1799: 717-25
71. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-68
72. Bartling B, Hofmann HS, Boettger T, et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005; 49: 145-54 (Pubitemid 40966741)
73. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class Ii histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112: 26-32 (Pubitemid 39249488)
74. Schuster-Bockler B, Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012; 488: 504-7
75. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85-93 (Pubitemid 10117303)
76. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984; 81: 6993-7 (Pubitemid 15216684)
77. Ferguson AT, Vertino PM, Spitzner JR, et al. Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-Aza-2′ deoxycytidineinduced cytotoxicity in human breast cancer cells. J Biol Chem 1997; 272: 32260-6 (Pubitemid 28011904)
78. Christman JK. 5-Azacytidine and 5-Aza- 2′ -deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95 (Pubitemid 34983483)
79. Patel K, Dickson J, Din S, et al. Targeting of 5-Aza-2′ -deoxycytidine residues by chromatin-associated Dnmt1 induces proteasomal degradation of the free enzyme. Nuc Acids Res 2010; 38: 4313-24
80. Issa JP, Kantarjian HM. Targeting DNA Methylation. Clin Cancer Res 2009; 15: 3938-46
81. Juttermann R, Li E, Jaenisch R. Toxicity of 5-Aza-2′ -deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91: 11797-801
82. Oka M, Meacham AM, Hamazaki T, et al. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-Aza-2′ -deoxycytidine. Oncogene 2005; 24: 3091-9 (Pubitemid 40695078)
83. Palii SS, Van Emburgh BO, Sankpal UT, et al. DNA methylation inhibitor 5-Aza-2′ -deoxycytidine induces reversible genome-wide dna damage that is distinctly influenced by dna methyltransferases 1 and 3b. Mol Cell Biol 2008; 28: 752-71
84. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-28
85. Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random dna demethylation in human cancer cell lines. PloS One 2011; 6: e17388
86. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-46
87. Momparler RL, Ayoub J. Potential of 5- Aza-2′ -deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001; 34(Suppl 4): S111-15
88. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-85 (Pubitemid 44629609)
89. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotech 2010; 28: 1069-78
90. Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-9
91. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84 (Pubitemid 44348499)
92. Miyanaga A, Gemma A, Noro R, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008; 7: 1923-30
93. Brazelle W, Kreahling JM, Gemmer J, et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 2010; 5: e14335
94. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292-300 (Pubitemid 32751627)
95. Sandor V, Bakke S, Robey RW, et al. Phase I Trial of the histone deacetylase inhibitor, depsipeptide (Fr901228, Nsc 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-28 (Pubitemid 34742100)
96. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of Ms-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23: 3912-22 (Pubitemid 46218694)
97. Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, Ms-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008; 14: 4517-25
98. Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin Cancer Res 2008; 14: 188-98 (Pubitemid 351377995)
99. Siu LL, Pili R, Duran I, et al. Phase I Study of Mgcd0103 given as a threetimes- per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1940-7
100. Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Inv New Drugs 2008; 26: 483-8
101. Traynor AM, Dubey S, Eickhoff JC, et al. Vorinostat (Nsc# 701852) in patients with relapsed non-small cell lung cancer: a wisconsin oncology network phase II study. J Thor Oncol 2009; 4: 522-6
102. Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol 2010; 28: 4507-12
103. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 56-62
104. Witta SE, Jotte RM, Konduri K, et al. randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012; 30: 2248-55
105. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-7 (Pubitemid 29036293)
106. Boivin AJ, Momparler LF, Hurtubise A, et al. Antineoplastic action of 5-Aza-2′ -deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 2002; 13: 869-74
107. Zhu WG, Lakshmanan RR, Beal MD, et al. DNA Methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61: 1327-33 (Pubitemid 34292551)
108. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089-93 (Pubitemid 37413444)
109. Belinsky SA, Grimes MJ, Picchi MA, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011; 71: 454-62
110. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361-9
111. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764-73
112. Lin J, Gilbert J, Rudek MA, et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res 2009; 15: 6241-9
113. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008; 14: 6296-301
114. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011; 1: 598-607
115. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94: 1087-92
116. Plumb JA, Strathdee G, Sludden J, et al. Reversal of drug resistance in human tumor xenografts by 2′ -Deoxy-5- azacytidine-induced demethylation of the Hmlh1 gene promoter. Cancer Res 2000; 60: 6039-44
117. Wu J, Hu CP, Gu QH, et al. Trichostatin a sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharm Sinica 2010; 31: 93-101
118. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80
119. Cooper SJ, von Roemeling CA, Kang KH, et al. Reexpression of tumor suppressor, Sfrp1, leads to antitumor synergy of combined Hdac and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther 2012; 11: 2105-15
120. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529-38 (Pubitemid 47365487)
121. Fu S, Hu W, Iyer R, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011; 117: 1661-9
122. Matei D, Fang F, Shen C, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72: 2197-205